D. Morgan

发表

Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR

Jean M. Severin, S. Davidsen, P. Hajduk, 1997 .

Purification and characterization of calmodulin from porcine renal medulla.

W. Y. Cheung, D. Morgan, T. Lynch, 1980, Archives of biochemistry and biophysics.

Specific in vitro activation of Ca,Mg-ATPase by vitamin D-dependent rat renal calcium binding protein (calbindin D28K).

S. Christakos, D. Morgan, A. Welton, 1986, Biochemical and biophysical research communications.

Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.

S. Davidsen, P. Tapang, D. Albert, 1998, Journal of Medicinal Chemistry.

Sodiumcalcium exchange in sarcolemmal vesicles from tracheal smooth muscle

D. Morgan, R. Slaughter, A. Welton, 1987 .

In Vivo Models of Inflammation

Christopher S. Stevenson, C. Stevenson, L. Marshall, 1999, Progress in Inflammation Research.

Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.

S. Davidsen, M. Michaelides, P. Tapang, 2001, Bioorganic & Medicinal Chemistry Letters.

Inhibitors of leukotriene action : potential use in asthma, inflammatory bowel disease, and cutaneous inflammation

D. Morgan, M. O'Donnell, J. Hurley, 1989 .

The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.

S. Davidsen, C. Wegner, P. Tapang, 1998, The Journal of pharmacology and experimental therapeutics.

Multiple pathways for signal transduction in the regulation of arachidonic acid metabolism in rat peritoneal macrophages.

D. Morgan, D. Dubourdieu, 1990, Biochimica et biophysica acta.

Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.

S. Davidsen, P. Tapang, D. Albert, 1997, European journal of pharmacology.

Chapter 7. Pulmonary and Antiallergy Agents

D. Morgan, M. O'Donnell, A. Welton, 1989 .

Modulation of rabbit airway smooth muscle responsiveness by respiratory epithelium. Involvement of an inhibitory metabolite of arachidonic acid.

K. Adler, J. N. Evans, D. Morgan, 1987, The American review of respiratory disease.

Interleukin‐1β induces cytosolic phospholipase a2 and prostaglandin h synthase in rheumatoid synovial fibroblasts

C. Anderson, W. Levin, R. Crowl, 1994 .

Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-α converting enzyme

K. Glaser, S. Davidsen, M. Michaelides, 2001 .

Ex vivo inhibition of β-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist

D. Albert, J. Summers, G. Carter, 1997, Inflammation Research.

Interleukin-1 beta induces cytosolic phospholipase A2 and prostaglandin H synthase in rheumatoid synovial fibroblasts. Evidence for their roles in the production of prostaglandin E2.

C. Anderson, W. Levin, R. Crowl, 1994, Arthritis and rheumatism.

Interleukin-1β induces cytosolic PLA2 in parallel with prostaglandin E2 in rheumatoid synovial fibroblasts

C. Anderson, W. Levin, D. Bolin, 2005, Agents and Actions.

Interleukin-1 beta stimulates cytosolic phospholipase A2 in rheumatoid synovial fibroblasts.

C. Anderson, D. Morgan, K. Hulkower, 1992, Biochemical and biophysical research communications.

Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo

S. Davidsen, S. Rabbani, Y. Guo, 2000, International journal of cancer.

Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.

S. Davidsen, M. Michaelides, D. Albert, 2001, Bioorganic & medicinal chemistry letters.

Are prostaglandins major mediators in perennial allergic rhinitis?

J. Marriott, D. Morgan, W. C. Lee, 1996, Rhinology.

Discovery of Selective Hydroxamic Acid Inhibitors of Tumor Necrosis Factor-α Converting Enzyme.

K. Glaser, S. Davidsen, M. Michaelides, 2010 .

Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.

S. Davidsen, D. Albert, J. Summers, 1998, Bioorganic & medicinal chemistry letters.

Inflammatory Processes:

D. Morgan, L. Letts, 2000, Progress in Inflammation Research.

Cancer and Inflammation

D. Morgan, U. Forssmann, M. Nakada, 2004, Progress in Inflammation Research.

Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction

L. Matrisian, R. DuBois, D. Morgan, 2003, British Journal of Cancer.

The physiology and biochemistry of normal and diseased lung.

D. Morgan, M. O'Donnell, A. Welton, 1987, Advances in clinical chemistry.

Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.

Yan Guo, Yujia Dai, S. Davidsen, 2002, Journal of medicinal chemistry.

Transforming growth factor beta mimetics: discovery of 7-[4-(4-cyanophenyl)phenoxy]-heptanohydroxamic acid, a biaryl hydroxamate inhibitor of histone deacetylase.

K. Glaser, H. Moses, G. Sheppard, 2002, Molecular cancer therapeutics.

Cytosolic calcium ion and arachidonic acid release and metabolism in macrophages.

A. Malgaroli, D. Morgan, S. Nicosia, 1991, European journal of pharmacology.

N-(carboxymethyl)-N-[3,5-bis(decyloxy)-phenyl]glycine (Ro 23-9358): a potent inhibitor of secretory phospholipases A2 with antiinflammatory activity.

V. Madison, H. Hendrickson, D. Morgan, 1993, Journal of medicinal chemistry.

ChemInform Abstract: Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR.

Karl A. Walter, Jean M. Severin, Stephen W. Fesik, 1997 .

Enhancement of the surface expression of tumor necrosis factor α (TNFα) but not the p55 TNFα receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors

K. Glaser, D. Morgan, Junling Li, 1999 .

Modulation of arachidonic acid metabolism: focus on phospholipase A2(S).

L. Marshall, D. Morgan, 1998, Drug news & perspectives.

The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.

S. Davidsen, D. Albert, M. Curtin, 1998, Bioorganic & medicinal chemistry letters.

Secretory phospholipase A2 inhibitors and calmodulin antagonists as inhibitors of cytosolic phospholipase A2

D. Morgan, W. Hope, Ting Chen, 2005, Agents and Actions.

Eicosanoid production and phospholipase A2 secretion by peritoneal macrophages from rats with adjuvant-induced arthritis

C. Anderson, D. Morgan, A. Hanglow, 1991, Agents and Actions.